stockrowErasca, Inc.
ERAS Healthcare Biotechnology
- EPS
- −16.7%
- Free cash flow
- −4.67%
Quarter to June 2026, against a year earlier
Follow ERAS
Alert me
Erasca, Inc. (ERAS) Return on assets
Erasca, Inc.'s return on assets over the twelve months to 30 June 2026 was −65.3%, down 37.5 percentage points from fiscal 2025 (−27.7%). Over the past ten years it has ranged from −112.7% (fiscal 2020) to −27.5% (fiscal 2023); the current reading is higher than 86% of that period. That is below the Biotechnology industry median of −46.1% and below the Healthcare sector median of −29.5%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −27.7% | 8.29 |
| FY2024 | −36.0% | (8.53) |
| FY2023 | −27.5% | 20.30 |
| FY2022 | −47.8% | (8.57) |
| FY2021 | −39.2% | 73.53 |
| FY2020 | −112.7% | (69.36) |
| FY2019 | −43.4% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| EWTX Edgewise Therapeutics, Inc. compare | 85.4% |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −5.32% |
| TVTX Travere Therapeutics, Inc. compare | −17.5% |
| CRSP CRISPR Therapeutics AG compare | −19.0% |
| MANE Veradermics Incorporated compare | −20.9% |
| DNTH Dianthus Therapeutics, Inc. compare | −21.8% |
| DFTX Definium Therapeutics, Inc. compare | −51.4% |
| ERAS Erasca, Inc. | −65.3% |
| COGT Cogent Biosciences, Inc. compare | −68.0% |
| Biotechnology industry median | −46.1% |
| Healthcare sector median | −29.5% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)